Here's your summary from Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug (https://www.youtube.com/watch?v=MvdpqkC5iIY) on the Bloomberg Television channel:
**TLDR:** Sarepta Therapeutics stock soared by 30% after FDA approval for gene therapy to treat Duchenne Muscular Dystrophy in patients aged four and above.
1. Sarepta Therapeutics received FDA approval for gene therapy to treat Duchenne Muscular Dystrophy in patients aged four and above, leading to a 30% increase in stock value.
2. The therapy was previously only available for children aged four and five, but now has no upper age limit for patients.
3. Analysts predict a significant increase in sales due to the expanded approval, with the stock receiving multiple upgrades.
#finance #tradfi #markets #stocks #stockmarket #bloomberg #macro